Category: Pharmaceuticals
The pre-clinical trials of saracatinib exhibited that it hinders collagen deposition and fibroblast activity, which are crucial aspects of lung fibrosis Saracatinib has completed Phase I development The United …
The company’s RP-L102 could offer a potentially curative therapeutic option for FA patients The treatment is already under Phase 1 and 2 clinical trials in the European Union Rocket …
The new joint venture will be dedicated towards the research and development of cannabinoid formulations for treating ophthalmic disorders and address significant unmet medical needs in the market A …
Pharmaceutical giant Eli Lilly has hit the headlines after company’s Chairman and CEO Dave Ricks publicized the launch of an affordable version of Humalog, its rapid-acting insulin brand. Eli …
In accordance with the preliminary results, the company looks forward to a Phase 2 trial by this year’s third quarter, in kids with achondroplasia. Ascendis Pharma A/S, the Denmark-based, …
Lynparza was the first PARP drug to reach the market after it was approved for ovarian cancer in U.S. Leading multinational pharmaceutical and biopharmaceutical firm, AstraZeneca Plc., has recently …
The U.S. Food & Drug Administration (FDA) has reportedly approved TAS-102 (trifluridine/tipiracil; Lonsurf, Taiho Oncology) for the treatment of adult patients afflicted with metastatic GEJ (gastroesophageal junction) adenocarcinoma. Reportedly, …
Eyenovia, Inc., has reportedly declared attaining positive results from its second MicroStat Phase III study, known as MIST-2. If reports are to be believed this study evaluated the efficacy …
The drug has been specifically developed for the nonalcoholic fatty liver disease (NASH) The clinical trial is expected to report by the third quarter of 2019 Boehringer Ingelheim (Boehringer), …
Agios Pharmaceuticals, Inc. has recently announced that the FDA has accepted the supplemental New Drug Application (sNDA) of the company for TIBSOVO®. Apparently, the drug would be used in …